

Removal of temporary benefit from the *Alberta Drug Benefit List (ADBL)*

Due to the shortage of Fortaz 6 g/Vial Injection (DIN 02212234) manufactured by GlaxoSmithKline, Ceftazidime 6 g/Vial Injection (DIN 00886963) manufactured by Fresenius Kabi Canada was added as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

GlaxoSmithKline has advised Alberta Blue Cross that the shortage of Fortaz 6 g/Vial Injection (DIN 02212234) has been resolved.

As a result, Ceftazidime 6 g/Vial Injection (DIN 00886963) will no longer be considered a temporary benefit for the *ADBL* **after April 14, 2016**.

Temporary benefit added to the *Alberta Drug Benefit List (ADBL)*

Due to the unavailability of Ciloxan 0.3% (Base) Ophthalmic Solution (DIN 01945270) manufactured by Alcon Canada Inc., Sandoz Ciprofloxacin 0.3% Ophthalmic Solution (DIN 02387131) manufactured by Sandoz Canada Inc. will be considered as a temporary benefit for the *Alberta Drug Benefit List (ADBL)*.

As of March 10, 2016, all claims for Sandoz Ciprofloxacin 0.3% Ophthalmic Solution (DIN 02387131) will be adjudicated to the price published in the most recent *Alberta Blue Cross Drug Price List (ABCDPL)* until further notice. The *ABCDPL* is available online at <https://www.ab.bluecross.ca/providers/pharmacy-home.html>.

If this situation continues to be a long-term matter, then this product is subject to the usual review process by the Expert Committee on Drug Evaluation and Therapeutics and must be approved by the Minister of Health for addition to the *ADBL* in order to remain as a benefit.

... continued from previous page

Product supply shortage addressed for *Alberta Drug Benefit List (ADBL)*

Alberta Blue Cross has been advised by Sandoz Canada Inc. that the shortage of Methotrexate (Preserved) 25 mg/ml Injection USP (DIN 02398427) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 14, 2016**.

METHOTREXATE SODIUM

25 MG / ML INJECTION

00002398427	METHOTREXATE (PRESERVED)	SDZ	\$ 4.4600
00002182777	METHOTREXATE SOD. (PRESERVED)	HSP	\$ 8.4472

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • 403-294-4041 (Calgary and area) • 1-800-361-9632 (toll free)

FAX 780-498-8406 (Edmonton and area) • FAX 1-877-305-9911 (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefits and supplemental claiming information to assist with the submission of your direct bill drug claims. Visit <https://www.ab.bluecross.ca/providers/pharmacy-home.php>



**The Blue Cross symbol and name are registered marks of the Canadian Association of Blue Cross Plans, an association of independent Blue Cross plans. Licensed to ABC Benefits Corporation for use in operating the Alberta Blue Cross Plan. *† Blue Shield is a registered trade-mark of the Blue Cross Blue Shield Association. ABC 82320.593 2016/03

